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Summary
Objectives: Themain objective of the present study was to detect point mutations at positions 86,
184, 1034, 1042, and 1246 of the Plasmodium falciparum multidrug resistance gene (pfmdr1) in
blood samples collected frommalaria patients in Chabahar, a harbor city located in Southeast Iran.
Methods: Twenty-six blood samples from patients infected with P. falciparum, who had a chlor-
oquine (CQ) response failure, were collected pre-treatment. Following treatment with CQ, drug
susceptibility was assessed using an in vivo test. Molecular detection of single nucleotide poly-
morphisms (SNPs) was carried out using the LightCycler hybridization probe assay.
Results: The pfmdr1 N86Y mutation was found in six isolates (23.1%). Mutations at the four other
positions were not observed in any isolates.
Conclusion: The present study showed nomutation at codon positions 184, 1034, 1042, and 1246 of
pfmdr1 in any of the Iranian P. falciparum isolates; thus these alleles cannot serve asmarkers for CQ
resistance in Iran.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Malaria still remains one of the leading causes ofmorbidity and
mortality in the world. Of the approximately 50million deaths
worldwideeachyear, about2millionareattributed tomalaria.
Drug resistance is one of the major factors contributing to the
resurgence of malaria, especially resistance to the most* Corresponding author.
E-mail address: dalimi4@yahoo.com (A. Dalimi).
1201-9712/$32.00 # 2008 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2008.01.004affordable drugs, such as chloroquine (CQ). Prior to the emer-
gence of resistance, CQ was considered a very effective, safe,
and inexpensive antimalarial drug.1 However, resistance to CQ
developed in the early 1960s at two foci, one in Southeast Asia
and the other in Latin America, and has spread to all areas
wheremalaria is present. It has been estimated that mortality
from falciparum malaria increases up to five-fold in areas
where resistance to the antimalarial CQ is established.1 To
reduce the mortality rate, understanding the mechanisms of
such resistance and the development of new treatments,
including new drugs, are urgently required.Published by Elsevier Ltd. All rights reserved.
pfmdr1 gene mutation in P. falciparum Iran 631Great progress has been made recently in studying the
mechanisms of drug action and drug resistance in malaria
parasites. These efforts are highlighted by the demonstration
of mutations in multiple-drug resistant genes. The emer-
gence and spread of multidrug-resistant Plasmodium falci-
parum has severely limited the therapeutic options for the
treatment of malaria.
Mutations in two genes, P. falciparum chloroquine resis-
tance transporter ( pfcrt) and P. falciparum multidrug resis-
tance ( pfmdr1) of P. falciparum have been reported to be
linked to CQ resistance. It has been proposed that point
mutations in the pfmdr1 gene producing amino acid changes
at positions 86, 184, 1034, 1042, and 1246 are associated with
CQ resistance.2 Results obtained from pfmdr1 single nucleo-
tide polymorphism (SNP) studies have indicated a significant
role for the N86Y mutation in contributing to resistance to
chloroquine.2,3 A point mutation (N86Y) resulting in an amino
acid change from asparagine to tyrosine at position 86 in the
pfmdr1 gene has been reported to be associated with in vitro
chloroquine resistance in isolates originating from various
regions of Asia and Africa.2,3
In Iran P. falciparum transmission mainly occurs in the
southeast of the country. Chabahar is a harbor city located
in Southeast Iran, where more than 85% of annual malaria
cases occur. P. falciparum chloroquine resistance cases
have been reported from Southeast Iran since the early
1980s.4—6 In a study carried out by Ursing et al. (2006),
polymorphisms in the pfmdr1 gene were detected by PCR-
RFLP (polymerase chain reaction-restriction fragment
length polymorphism) and sequencing methods.6 The main
objective of the present study was to detect point muta-
tions at positions 86, 184, 1034, 1042, and 1246 of the P.
falciparum multidrug resistance 1 gene ( pfmdr1) in P.
falciparum isolates collected from malaria patients in
Chabahar, in order to evaluate if pfmdr1 point mutations
could be considered as a useful tool in monitoring
emergence of CQ and related drugs resistance.
Materials and methods
Blood samples
Twenty-six blood samples were taken from patients
infected with P. falciparum, who had a CQ response fail-
ure, living in Chabahar, Southeast Iran from March to
December 2004. Patients were selected from those
referred to the City Public Health Center for malaria
treatment. Sampling (5 ml blood) was done only from
patients who gave consent to participate in the study.
The mean age of patients was 35 years (range 12—60
years). The infection was assessed by microscopic exam-
ination of thick and thin smears before starting treatment.
All the patients were treated with CQ (25 mg/kg over 3
days), the first-line treatment according to the Iranian
Ministry of Health guidelines at the time of the study.
CQ susceptibility was assessed using an in vivo test.7 A
period of 28 days of in vivo testing was conducted accord-
ing to the World Health Organization (WHO) protocol to
assess the efficacy of standard supervised CQ therapy.7
Discrimination between recrudescence and new infection
was done based on the patient’s history during the 28-day
follow-up period. The study received ethical clearance fromthe institutional ethical review board (Ethical Approval
Reference Committee, Medical Sciences Faculty).
All the blood samples for PCR were taken before treat-
ment. The samples were transferred to the Parasitology
Laboratory of Tarbiat Modares University and stored at
20 8C until use for the molecular study.
Plasmodium falciparum reference strains
Three P. falciparum strains adapted to culture medium were
selected as reference strains. 3D7 was the CQ-sensitive strain
while W2 and 7G8 were selected as CQ-resistant strains.
These strains were generously provided by F. de Monbrison
from Claude Bernard University, Lyon, France. The dis-
patched reference isolates were spotted on Whatmann filter
paper and air-dried. The DNA was isolated from the dried
spots and blood samples using QIAamp DNA mini kit (Qiagen,
Germany).
Detection of pfmdr1 mutation
Detection of mutations was carried out with LightCycler
using hybridization probes according to the method
described by de Monbrison et al. (2003).8 For pfmdr1 muta-
tions, hybridization probes consisted of two different oligo-
nucleotides that bind to an internal sequence amplified by
forward and reverse primers. The sensor probe, labeled at
the 30 endwith fluorescein, is designed to themutation sites.
The anchor probe, labeled at the 50 end with LightCycler Red
640 and phosphorylated at the 30 end to prevent extension by
Taq polymerase, is designed to the conserved sequences
adjacent to the mutation sites. Both probes, localized on
the same DNA strand, could hybridize in a head-to-tail
arrangement, bringing the two fluorescent dyes into close
proximity.8
Primers and probes were designed according to the de
Monbrison study, checked with the GenBank facility for
accuracy, and then synthesized by TIB MOL BIOL (Berlin,
Germany) to detect mutations of pfmdr1 (GenBank Accession
No. X56851).
PCR amplification
PCR master mix was prepared using the Roche LC kit (Roche
Molecular Biochemicals, Germany). For pfmdr1 codons 86
and 184, the PCR program was as follows: 9 min at 95 8C, 35
cycles of 95 8C for 10 s, 54 8C for 10 s, and 65 8C for 40 s;
followed by a melting curve analysis from 35 8C to 75 8C at
0.2 8C/s. For pfmdr1 codons 1034—1042 and 1246, the con-
ditions for cycling were: 9 min at 95 8C, 40 cycles of 95 8C for
10 s, 54 8C for 10 s, and 65 8C for 55 s; followed by a melting
curve analysis from 35 8C to 80 8C at 0.2 8C/s.
Reference isolates were included in each run as reference
controls. For recovery of DNA fragments from agarose gel, a
PCR purification kit (Fermentas, Lithuania) was used.
Sequencing of both strands was done using the primers by
MWG Company (Basel, Switzerland). Purified PCR products
were cloned into a 2886 bp PT Z57R/T vector (Fermentas,
Lithuania). The ligated product was transformed into Escher-
ichia coli TG1 competent cells, and the plasmids from posi-
tive colonies were selected for sequencing.
Table 1 Melting temperatures of different alleles of pfmdr1 codons (N86Y, Y184F, S1034C, N1042D, D1246Y) in three reference
strains and isolates
pfmdr1 gene codons Melting temperatures (8C) of alleles
3D7 W2 7G8 Wild-type Mutant-type
Codon 86 50.56  0.4 54.7  0.6 (M*) 50.65  0.5 50.36  0.11 54.15  0.11 (M*)
Codon 184 53.57  0.5 53.55  0.58 57.90  0.5 (M*) 52.48  0.31 -
Codon 1034—1042 57.13  0.65 57.14  0.75 64.08  0.7 (M*) 56.79  0.15 -
Codon 1246 52.54  0.22 52.57  0.26 57.85  0.5 (M*) 52.42  0.06 -
Melting temperatures are reported as means  standard deviation from four independent assays.
M*: mutant in that position.
Table 2 Frequency of codon positions of Pfmdr1 mutation
among 26 human blood isolates from Chabahar, Southeast Iran
Gene Codon positions Frequency (%)
pfmdr1 Wild (N86) 20 (76.9)
Mutant (Y86) 6 (23.1)
Wild 184, 1034,
1042, 1246
26 (100)
Mutant 184, 1034,
1042, 1246
0 (0)
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In the present study, a point mutation in the pfmdr1 gene of P.
falciparum isolates was successfully detected. As shown in
Table 1, our isolates showed mutant nucleotide only atFigure 1 DNA sequencing of pfmdr1 gene
Figure 2 Melting curve analysis of patient isolates and reference st
from top to bottom (mutant): KhT, GhA, SaS, W2 (Ref. strain), ZaB, RiB
RbB, HaD, SaR, ZaA, AbB, GhSA, LaF, 3D7 (Ref. strain).position 86. The 3D7 reference strain showed the wild pfmdr1
genotype at all codon positions: 86, 184, 1034, 1042, and
1246. The W2 reference strain showed mutant nucleotide at
position 86, while the 7G8 reference strain showed mutant
genotype at codon positions 184, 1034, 1042, and 1246 as
well as wild genotype at codon position 86.
The frequency of the pfmdr1 mutation among the 26
human blood samples is shown in Table 2. The pfmdr1
N86Y mutation was found in six isolates (23.1%). In the four
other positions (184, 1034, 1042, and 1246) no mutations
were observed. PCR products sequencing and melting tem-
perature analysis gave similar results (Figure 1).
Melting curve analysis of isolates and reference strains for
detection of the N86Y pfmdr1 mutation is shown in Figure 2.
According to the results, the isolates show A to T nucleotide
exchange. These types of alleles showed a perfect match
with sensor probe. Their Tm curves are similar to W2 and 7G8
strains.with polymorphic codon at position 86.
rains for detection of N86Y mutation in pfmdr1 gene. Right curve
, 44. Left curve from top to bottom (wild type): 7G8 (Ref. strain),
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In the past, malaria was highly endemic in most parts of Iran.
In 1924, it was estimated that out of a population of 13 mil-
lion, 4—5 million people had clinical malaria. An organized
malaria control programwas started before the SecondWorld
War, and in 1957 a strategy of malaria eradication was
endorsed by the Government.9 Now, the Iranian Government
belongs to the WHO Eastern Mediterranean Region (EMR) and
sustains a strong malaria control program.
Although, there has been a decreasing trend in themalaria
incidence in recent years, the southeastern corner of Iran,
which consists of Sistan and Baluchistan Province, Hormozgan
Province, and the tropical part of Kerman Province with a
combined population of approximately 3 million, is consid-
ered to be a ‘refractory malaria region’. The annual parasite
incidence (API) was reported to be 8.74 per 1000 population
in 1997. In this part of the country, malaria belongs to the
oriental type; hence it is difficult to control. Inherent pro-
blems are the drug resistance of P. falciparum and the vector
resistance to insecticides, with the additional complication
of the importation of malaria, mostly P. falciparum, from
Afghanistan and, to a lesser extent, Pakistan.9 According to
an Iranian Ministry of Health report, less than 15 000 malaria
cases were detected in the malaria region in 2006; of these,
30% were not in Iranian people. In our study 19%, 80%, and 1%
ofmalaria infected cases detectedwere due to P. falciparum,
Plasmodium vivax, and mixed infection, respectively. Since
the early 1980s, the major problem in the region has been
considered to be CQ resistance.4—6
Mutations in the P. falciparum multidrug resistance gene
( pfmdr1) of P. falciparum have been reported to be linked to
chloroquine resistance. It has been indicated that P. falci-
parum can showmutation in its genome. For its survival it can
delete certain genes (or a portion) that are not required for
its growth and it has the capability to regulate its genes under
various stages of its life cycle and under unfavorable envir-
onmental conditions. Similarly, under drug pressure it allows
mutations to settle in the target genes.2 Epidemiological
studies have shown that the frequency of chloroquine-resis-
tant mutants varies among isolated parasite populations in
most malarial endemic countries.
pfmdr1 point mutations depend on the parasite genetic
background and can significantly affect parasite suscept-
ibility to a wide range of antimalarials in a strain-specific
manner. Some field studies support the linkage of this muta-
tion with chloroquine resistance while others do not. Results
obtained from some pfmdr1 SNP studies indicate a signifi-
cant role for the N86Ymutation in contributing to resistance
to chloroquine.10 P. falciparum isolates from Malaysia, Indo-
nesia, Guinea-Bissau, Nigeria, and Sub-Saharan Africa have
shown the N86Y mutation among the chloroquine-resistant.
A high prevalence of mutations in pfmdr1 was observed in
Cambodian isolates.11 In Thailand, pfmdr1 Y86 and 1034C
mutants have been reported at a significant level.12 But
studies from Uganda, Laos, Cameroon, South Africa, Brazil,
and the Peruvian Amazon have reported that this mutation is
not predictive of treatment outcome.13—19 Some studies
have shown that the pfmdr1 Y86mutation causes an increase
in sensitivity to mefloquine and artemisinin,3,20 and this
could be considered in drug treatment strategies in endemic
areas.In the present study, among 26 CQ-resistant isolates, six
isolates showed N86Y mutations in the pfmdr1 gene. In a
study carried out by Ursing et al. (2006) in 100 isolates from
the same area, polymorphism at codon position 86 of the
pfmdr1 gene was reported, while the 184F allele was
observed in 92% of the analyzed infections and no variation
was found in the SNPs of pfmdr1 at positions 1034, 1042, and
1246. They used PCR-RFLP and sequencing methods for their
investigation.6
In conclusion, the present study showed no mutation in
pfmdr1 at codon positions 184, 1034, 1042, and 1246 in any of
the Iranian P. falciparum isolates, and thus these alleles
cannot serve as markers for CQ resistance in Iran. In contrast,
N86Y mutations may be considered as resistance markers for
studying CQ resistance in endemic areas. Based on the pre-
sent results, it is proposed that pfmdr1 alone is not sufficient
to provide chloroquine resistance and that other gene muta-
tions, such as in pfcrt are necessary for the determination of
drug resistance.
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